Loading company…
PharmAbcine develops therapeutic antibodies for cancer and inflammatory diseases and provides antibody panning services.
Founded in 2008 and based in Daejeon, South Korea, PharmAbcine develops fully human therapeutic monoclonal antibodies for cancer and inflammatory diseases. Its technologies include human antibody libraries, antibody development and bispecific antibody engineering. The company’s programs include Olinvacimab, PMC-309, PMC-402 and PMC-403, spanning oncology, immuno-oncology, ophthalmology and pulmonology. It also offers antibody panning services.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in